Randomised trial, 2023
Can neurofeedback targeting emotion brain regions help people with PMDD?
Neurofeedback targeting the amygdala (a brain region that processes emotions) significantly reduced anger and other emotional symptoms compared to control neurofeedback. Improvement was stronger in people who learned more from the training.
What they did
27 people with PMDD (mean age 33.57 years) were randomly assigned to neurofeedback targeting the amygdala or control neurofeedback. Both groups completed 11 sessions over 3 menstrual cycles, with follow-up 3 months later.
What they found
The amygdala-targeting group showed significant improvement in emotional symptoms, especially anger, compared to control at 3-month follow-up. People who learned more during training showed greater overall symptom improvement.
What it means for you
Amygdala-targeted neurofeedback might be a non-invasive treatment for emotional symptoms in PMDD. Main limitations are the very small sample size (27 total) and lack of sham placebo control, making it unclear if benefits come from brain training or from expectation.
27
Participants
11
Neurofeedback sessions
3
Menstrual cycles
About the study
- Original title
- Limbic self-neuromodulation as a novel treatment option for emotional dysregulation in premenstrual dysphoric disorder (PMDD); a proof-of-concept study
- Authors
- Tene O, Bleich Cohen M, Helpman L et al.
- Journal
- Psychiatry and clinical neurosciences
- Year
- 2023
- Study design
- Randomised trial
- What was tested
- Amygdala-targeting neurofeedback versus control neurofeedback, 11 sessions over 3 menstrual cycles
- Open access
- Yes
- Read the paper
- doi.org/10.1111/pcn.13574
Original abstract
Aim: To assess the efficacy of a novel neurofeedback (NF) method, targeting limbic activity, to treat emotional dysregulation related to premenstrual dysphoric disorder (PMDD). Methods: We applied a NF probe targeting limbic activity using a functional magnetic resonance imaging-inspired electroencephalogram model (termed Amyg-EFP-NF) in a double-blind randomized controlled trial. A frontal alpha asymmetry probe (AAS-NF), served as active control. Twenty-seven participants diagnosed with PMDD (mean age = 33.57 years, SD = 5.67) were randomly assigned to Amyg-EFP-NF or AAS-NF interventions with a 2:1 ratio, respectively. The treatment protocol consisted of 11 NF sessions through three menstrual cycles, and a follow-up assessment 3 months thereafter. The primary outcome measure was improvement in the Revised Observer Version of the Premenstrual Tension Syndrome Rating Scale (PMTS-OR). Results: A significant group by time effect was observed for the core symptom subscale of the PMTS-OR, with significant improvement observed at follow-up for the Amyg-EFP group compared with the AAS group [F(1, 15)=4.968, P = 0.042]. This finding was specifically robust for reduction in anger [F(1, 15) = 22.254, P < 0.001]. A significant correlation was found between learning scores and overall improvement in core symptoms (r = 0.514, P = 0.042) suggesting an association between mechanism of change and clinical improvement. Conclusion: Our preliminary findings suggest that Amyg-EFP-NF may serve as an affordable and accessible non-invasive treatment option for emotional dysregulation in women suffering from PMDD. Our main limitations were the relatively small number of participants and the lack of a sham-NF placebo arm.
Reproduced under CC-BY.
Topics
Related studies
Study, 2026
How do women with PMDD process emotions differently in their brains?
Case-control study, 2026
Do women with PMS handle emotions differently at different times of the cycle?
Systematic review, 2025
Do people with PMDD and severe PMS have difficulties with emotion regulation?
Randomised trial, 2007
Does paroxetine work better if taken daily or just during your luteal phase for PMDD?
Study, 2025
Do women with PMDD who experienced childhood trauma have more trouble recognizing emotions?
Randomised trial, 2024
Does emotion-focused therapy help PMDD symptoms?